⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

May 10, 2024Translational OncologyOpen Access

HMGB2 is a biomarker associated with poor prognosis promoting radioresistance in glioma by targeting base excision repair pathway

Wei Han Huandi Zhou Xinyuan Zhang Haonan Li Xuetao Han Linlin Su Lei Tian Xiaoying Xue

View Full Paper

Ask AI

Bookmark

Share

Abstract

High mobility group box 2 (HMGB2) is considered as a biomarker of poor prognosis in various cancers.This study aims to investigate the effect and mechanism of HMGB2 in gliomas.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Han et al. (2024) studied this question.

synapsesocial.com/papers/68e6ab16b6db64358762d136 https://doi.org/10.1016/j.tranon.2024.101977

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Proteomic Analysis of Spatial Heterogeneity Identifies HMGB2 as Putative Biomarker of Tumor Progression in Adult-Type Diffuse Astrocytomas2024 · 3 citations
2HMGN2 accelerates the proliferation and cell cycle progression of glioblastoma by regulating CDC20 expression2024 · 8 citations
3Multiple functions of HMGB1 in cancer2024 · 48 citations
4Abstract 7376: HMGB2-mediated radioresistance of glioblastoma stem cellsOriginal Research · 2026
5Expression and Survival Analysis Show High Mobility Group (HMG) Family as Prognostic Biomarkers in Breast CancerOriginal Research · 2026